Cardiovascular monitoring · UK 2026
The annual heart test
built for family history.
At-home cardiovascular blood testing for people with a family history of heart disease.
Join the waitlist
Why Akoma exists
“A family history of heart disease is one of the strongest predictors of cardiovascular risk — and one of the clearest reasons to monitor it every year.”
The gap
Risk isn’t a one-year answer.
When heart disease runs in your family, a single snapshot isn’t enough. Akoma tests the same markers every year so you can see whether things are moving in the right direction.
1 in 3
UK adults have a family history of cardiovascular disease
0%
Sample success rate
0
Cardiovascular biomarkers per panel
0%
UK-accredited lab processing
How it works
Simple. At home. Annual.
Tell us your family history
We build your personalised cardiovascular panel around it.
Your kit arrives at the door
Finger-prick at home. Post it back in the prepaid envelope.
Results in plain English
What each marker means, and what to do if anything needs attention.
Renews automatically every year.
No reminders. Cancel anytime.
Results & tracking
Understand your results,
not just your numbers.
Every marker translated into plain English — what it means and whether it’s improving. Your first panel sets a baseline; each year builds on it.
Heart particle risk
OptimalImproving year on year
Artery inflammation
OptimalSignificantly better
Inherited risk marker
Keep watchingStable — monitor annually
Cardiovascular health score · 2022 – 2025 ↑ improving
Next panel ships each year · Full report includes 8 markers
Your annual panel
Eight markers that map your heart risk.
ApoB
Plaque-building particles in your arteries.
Lp(a)
An inherited risk marker, often untested.
hs-CRP
Silent inflammation that standard tests miss.
HbA1c
Blood sugar control and diabetes risk.
Full Lipid Panel
Cholesterol, LDL, HDL, and triglycerides.
ApoA
The protective side of your cholesterol.
Homocysteine
Arterial damage linked to hereditary variants.
Full Blood Count
Oxygen delivery and blood cell health.
Be first
Know your risk before your body tells you.
Early access when Akoma launches in the UK.
